S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
NASDAQ:MRNS

Marinus Pharmaceuticals Stock Competitors

$11.08
+0.37 (+3.45%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.42
$11.19
50-Day Range
$9.31
$12.81
52-Week Range
$9.10
$20.04
Volume
92,150 shs
Average Volume
240,697 shs
Market Capitalization
$407.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16

Marinus Pharmaceuticals (NASDAQ:MRNS) Vs. PTGX, MYOV, ENTA, IMGN, ADCT, AMRN, NGM, XENE, FGEN, and QURE

Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include Protagonist Therapeutics (PTGX), Myovant Sciences (MYOV), Enanta Pharmaceuticals (ENTA), ImmunoGen (IMGN), ADC Therapeutics (ADCT), Amarin (AMRN), NGM Biopharmaceuticals (NGM), Xenon Pharmaceuticals (XENE), FibroGen (FGEN), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry.

Marinus Pharmaceuticals vs.

Myovant Sciences (NYSE:MYOV) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Myovant Sciences has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Marinus Pharmaceuticals received 186 more outperform votes than Myovant Sciences when rated by MarketBeat users. Likewise, 72.15% of users gave Marinus Pharmaceuticals an outperform vote while only 66.56% of users gave Myovant Sciences an outperform vote.

CompanyUnderperformOutperform
Myovant SciencesOutperform Votes
213
66.56%
Underperform Votes
107
33.44%
Marinus PharmaceuticalsOutperform Votes
399
72.15%
Underperform Votes
154
27.85%

Marinus Pharmaceuticals has lower revenue, but higher earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant Sciences$59.32 million25.69-$255.13 million-$2.61-6.26
Marinus Pharmaceuticals$1.72 million236.84-$67.47 million-$2.47-4.49

In the previous week, Marinus Pharmaceuticals had 3 more articles in the media than Myovant Sciences. MarketBeat recorded 8 mentions for Marinus Pharmaceuticals and 5 mentions for Myovant Sciences. Marinus Pharmaceuticals' average media sentiment score of 0.44 beat Myovant Sciences' score of 0.21 indicating that Marinus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myovant Sciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Marinus Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Myovant Sciences presently has a consensus target price of $25.40, indicating a potential upside of 55.54%. Marinus Pharmaceuticals has a consensus target price of $34.60, indicating a potential upside of 212.27%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Myovant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Marinus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 86.9% of Marinus Pharmaceuticals shares are held by institutional investors. 5.1% of Myovant Sciences shares are held by insiders. Comparatively, 3.5% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Myovant Sciences has a net margin of -164.51% compared to Marinus Pharmaceuticals' net margin of -572.12%. Myovant Sciences' return on equity of 0.00% beat Marinus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Myovant Sciences -164.51% N/A -32.82%
Marinus Pharmaceuticals -572.12% -86.10% -61.91%

Summary

Marinus Pharmaceuticals beats Myovant Sciences on 12 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Marinus Pharmaceuticals (NASDAQ:MRNS) vs. Its Competitors

TypeMarinus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$407.37M$5.86B$5.02B$7.96B
Dividend YieldN/A2.61%2.05%2.54%
P/E Ratio-4.4916.5722.5923.69
Price / Sales236.84570.152,443.64281.05
Price / CashN/A146.2661.85204.50
Price / Book5.495.696.246.57
Net Income-$67.47M$95.70M$96.11M$154.60M
7 Day Performance7.36%2.25%2.34%2.28%
1 Month Performance-12.62%-11.51%-10.08%-7.83%
1 Year Performance-18.53%5.87%10.48%30.83%

Marinus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTGX
Protagonist Therapeutics
1.7265 of 5 stars
$34.04
+0.6%
$59.71
+75.4%
+39.2%$1.62B$28.63M-14.1279
MYOV
Myovant Sciences
1.9881 of 5 stars
$16.33
+1.0%
$25.40
+55.5%
-32.9%$1.52B$59.32M-6.26407News Coverage
ENTA
Enanta Pharmaceuticals
2.2681 of 5 stars
$74.81
+3.8%
$90.88
+21.5%
+75.4%$1.52B$97.07M-19.13141
IMGN
ImmunoGen
1.8931 of 5 stars
$7.32
+3.7%
$9.50
+29.8%
+14.2%$1.48B$132.30M-21.5379
ADCT
ADC Therapeutics
1.9917 of 5 stars
$21.25
+0.4%
$45.20
+112.7%
-40.4%$1.46B$2.34M-6.48208
AMRN
Amarin
1.785 of 5 stars
$3.61
+2.2%
$11.20
+210.2%
-23.5%$1.43B$614.06M89.252,020
NGM
NGM Biopharmaceuticals
2.3792 of 5 stars
$18.43
+1.5%
$35.78
+94.1%
-26.8%$1.43B$87.37M-11.45210Insider Selling
XENE
Xenon Pharmaceuticals
2.2998 of 5 stars
$27.45
+5.8%
$44.00
+60.3%
+140.4%$1.42B$32.17M-16.84129Gap Up
FGEN
FibroGen
2.1048 of 5 stars
$15.08
+3.6%
$29.50
+95.6%
-64.3%$1.40B$176.32M-6.47599
QURE
uniQure
2.4281 of 5 stars
$29.35
+1.9%
$60.15
+104.9%
-38.2%$1.36B$37.51M4.32332
MOR
MorphoSys
1.2115 of 5 stars
$9.88
+1.6%
$25.46
+157.7%
-65.1%$1.35B$374.30M-7.48615
ALXO
ALX Oncology
2.5333 of 5 stars
$33.10
+0.7%
$98.00
+196.1%
-55.0%$1.34B$1.18M-17.8023High Trading Volume
ORGO
Organogenesis
2.6748 of 5 stars
$10.40
+0.5%
$24.00
+130.8%
+98.9%$1.34B$338.30M22.61910
NRIX
Nurix Therapeutics
2.2 of 5 stars
$29.82
+3.4%
$53.17
+78.3%
-33.5%$1.33B$17.82M-12.482,020News Coverage
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$77.50
+1.5%
$179.50
+131.6%
-36.8%$1.33BN/A-5.2942
AXSM
Axsome Therapeutics
2.6514 of 5 stars
$35.13
+2.7%
$100.28
+185.4%
-57.5%$1.32BN/A-10.4960
RXDX
Prometheus Biosciences
2.3114 of 5 stars
$33.50
+4.1%
$42.33
+26.4%
+24.3%$1.30B$1.23M0.0026Analyst Upgrade
News Coverage
Gap Up
High Trading Volume
KROS
Keros Therapeutics
2.3598 of 5 stars
$55.35
+2.5%
$85.00
+53.6%
-30.8%$1.30B$10M-20.4235Analyst Revision
Positive News
AMRX
Amneal Pharmaceuticals
2.1315 of 5 stars
$4.26
+0.5%
$7.40
+73.7%
-2.1%$1.28B$1.99B47.336,000Negative News
CRNX
Crinetics Pharmaceuticals
2.3448 of 5 stars
$26.71
+1.3%
$36.80
+37.8%
+93.0%$1.27B$70K-9.6193Analyst Upgrade
ENDP
Endo International
1.9648 of 5 stars
$5.26
+0.2%
$6.60
+25.5%
-1.9%$1.23B$2.90B18.793,397
RNA
Avidity Biosciences
1.8865 of 5 stars
$25.88
+2.1%
$43.00
+66.2%
-26.3%$1.21B$6.79M-10.5682
RVNC
Revance Therapeutics
2.5781 of 5 stars
$16.64
+2.2%
$25.20
+51.4%
-32.3%$1.19B$15.32M-3.71470Insider Buying
GHRS
GH Research
1.8667 of 5 stars
$23.54
+1.7%
$31.06
+32.0%
N/A$1.19BN/A0.008Earnings Report
Analyst Report
High Trading Volume
CMPS
COMPASS Pathways
1.9 of 5 stars
$28.12
+2.0%
$79.86
+184.0%
-48.7%$1.17BN/A-16.642,020High Trading Volume
CNTA
Centessa Pharmaceuticals
2.3667 of 5 stars
$12.97
+1.0%
$38.00
+193.0%
N/A$1.17BN/A0.002,021Analyst Downgrade
Insider Buying
INVA
Innoviva
1.7165 of 5 stars
$16.72
+0.2%
N/A+56.6%$1.16B$336.79M5.365Positive News
PRTC
PureTech Health
1.3582 of 5 stars
$39.70
+0.2%
$74.00
+86.4%
-3.0%$1.14B$11.77M0.0066
PMVP
PMV Pharmaceuticals
2.5315 of 5 stars
$24.92
+5.4%
$53.67
+115.4%
-45.7%$1.13BN/A9.4044
MNKD
MannKind
1.6498 of 5 stars
$4.48
+1.8%
$6.30
+40.6%
+54.5%$1.13B$65.14M-14.00241
DAWN
Day One Biopharmaceuticals
2.1598 of 5 stars
$17.98
+0.1%
$37.33
+107.6%
N/A$1.11BN/A0.0020Insider Selling
High Trading Volume
DICE
DICE Therapeutics
1.825 of 5 stars
$28.62
+2.7%
$49.00
+71.2%
N/A$1.09BN/A0.002,021News Coverage
MGNX
MacroGenics
2.0131 of 5 stars
$17.60
+2.2%
$34.29
+94.8%
-24.5%$1.08B$104.88M-7.33370
MRUS
Merus
2.2631 of 5 stars
$27.09
+3.1%
$40.20
+48.4%
+50.2%$1.05B$29.94M-11.68117High Trading Volume
NUVL
Nuvalent
1.4998 of 5 stars
$21.74
+11.6%
$37.00
+70.2%
N/A$1.05BN/A0.002,021
ARCT
Arcturus Therapeutics
2.2681 of 5 stars
$39.33
+2.0%
$64.82
+64.8%
-60.7%$1.04B$9.54M-5.23118
DSGN
Design Therapeutics
1.6065 of 5 stars
$18.56
+6.2%
$35.33
+90.4%
N/A$1.03BN/A0.0015
AMPH
Amphastar Pharmaceuticals
2.1981 of 5 stars
$21.28
+0.9%
$21.50
+1.0%
+13.1%$1.02B$349.85M29.561,980Positive News
TNGX
Tango Therapeutics
2.0381 of 5 stars
$11.08
+2.6%
$16.50
+48.9%
N/A$970.01MN/A0.004News Coverage
EWTX
Edgewise Therapeutics
1.9481 of 5 stars
$19.59
+5.9%
$34.25
+74.8%
N/A$965.71MN/A0.0019
RANI
Rani Therapeutics
1.5 of 5 stars
$19.65
+19.6%
$23.50
+19.6%
N/A$962.89MN/A0.002,021Analyst Revision
KNSA
Kiniksa Pharmaceuticals
2.1781 of 5 stars
$13.80
+3.0%
$29.00
+110.1%
-24.1%$950.65MN/A-5.39168
RPTX
Repare Therapeutics
2.7 of 5 stars
$22.71
+0.3%
$48.43
+113.2%
-39.6%$947.80M$140K-8.98102
ZEAL
Zealand Pharma A/S
0.8798 of 5 stars
$21.39
+0.6%
N/A-42.8%$933.01M$54.13M-4.93329
MCRB
Seres Therapeutics
1.9769 of 5 stars
$10.11
+4.3%
$20.83
+106.1%
-60.1%$928.57M$33.22M-26.61155
RAPT
RAPT Therapeutics
2.6331 of 5 stars
$30.89
+1.7%
$60.17
+94.8%
+22.3%$912.68M$5.04M-12.6668
VNDA
Vanda Pharmaceuticals
2.2581 of 5 stars
$16.29
+0.2%
$20.00
+22.8%
+19.3%$907.55M$248.17M26.70292News Coverage
IDYA
IDEAYA Biosciences
2.1164 of 5 stars
$23.54
+4.2%
$32.29
+37.2%
+34.4%$906.22M$19.54M-21.4062Analyst Report
Gap Up
SNDX
Syndax Pharmaceuticals
1.7481 of 5 stars
$18.02
+3.6%
$28.00
+55.4%
-24.9%$890.04M$1.52M-9.9043
ZYME
Zymeworks
2.2931 of 5 stars
$18.95
+3.7%
$49.38
+160.6%
-64.9%$882.20M$38.95M-4.54354High Trading Volume
This page was last updated on 12/9/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.